Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
LP

OTC · LPHM

Lee Pharmaceuticals, Inc.

Financial Services · Shell Companies

$0.10

Down-$0.00 (-0.90%)

Updated Aug 23, 2026, 8:46 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
273.2K
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
— – —
Volume
172.85K
Avg. volume
49.41K

Price performance

LPHM price history

1M range · 0 trading sessions · Daily adjusted prices

LPHM does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LPHM news

The latest Smart Investors Daily articles mentioning LPHM.

Stock researchCompany · Overview

LPHM research

Overview

Company profile and research snapshot.

Company profile

Lee Pharmaceuticals, Inc. manufactures personal care and cosmetic products. The company specializes in personal care products, such as lip balm for chapped lips, nasal spray, nail care products, depilatories, and quit smoking items. Its products category includes aloe vera products, antacids, baby care, cosmetics and douche, cough and cold products, depilatories and waxes, laxatives, lip balm products, men's personal care, oral care, pain relievers, personal care, skin care, tobacco accessories, topical ointments/creams, and vitamins and nutritional items. The company also provides private label and contract manufacturing services. It offers its products through retailers and wholesalers, as well as online. The company was incorporated in 1971 and is based in South El Monte, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Nov 27, 2025

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

BEIJING , Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to maintain the achieved weight loss and improved long-term adherence.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By